(Q39212469)

English

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

scientific article published on 10 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

Alexandria P. Cogdill

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Zachary A. Cooper

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

David E. Fisher

20

object named as

David E Fisher

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

18

object named as

Patrick Hwu

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

14

object named as

F Stephen Hodi

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

21

object named as

Jennifer A Wargo

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Dennie T Frederick

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Adriano Piris

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Cecilia Lezcano

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Cristina R Ferrone

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Devarati Mitra

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Andrea Boni

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Lindsay P Newton

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Chengwen Liu

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Weiyi Peng

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Ryan J Sullivan

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Donald P Lawrence

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Willem W Overwijk

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Gregory Lizée

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

George F Murphy

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Keith T Flaherty

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

0 references

publication date

10 January 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Clinical Cancer Research

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1225-1231

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Biological challenges of BRAF inhibitor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Resistance to BRAF inhibition in melanomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

MEK1 mutations confer resistance to MEK and B-RAF inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Genetics of melanoma tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

10 September 2017

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

14 September 2017

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752683

21 August 2018

Identifiers

10.1158/1078-0432.CCR-12-1630

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23307859%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39212469&oldid=1855211124"